I am the Principal Investigator for this phase 2 trial looking at clinical efficacy and immunomodulatory effects of Interleukin-12 in myeloma patients in the plateau phase.
Clinical response is the main endpoint of the trial.
Correlative laboratory studies include looking at changes in T cell repertoires and response to vaccines with and without IL-12. I am the Principal Investigator for this trial, which complements the trials described above. We will focus future efforts on determining if the gene products are candidates for tumor vaccines. R. A. Kyle, and M. A. Gertz, Editors. The Parthenon Publishing Group, 1999.